ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM
Abstract Number: 2025
Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients
SLE – Etiology & Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 2609
Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy
Systemic Sclerosis & Related Disorders – Clinical Poster III
9:00AM-11:00AM
Abstract Number: 2000
Anti-inflammatory Effect of Novel Spleen Tyrosine Kinase Inhibitor, SKI-O-592, on Fibroblast-like Synoviocyte in Rheumatoid Arthritis and THP-1 Cell
RA – Etiology & Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 2003
Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5
RA – Etiology & Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 2618
Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients
Systemic Sclerosis & Related Disorders – Clinical Poster III
9:00AM-11:00AM
Abstract Number: 2103
Anti-TNF Therapy in Patients with HIV Infection
Infection-Related Rheumatic Disease Poster
9:00AM-11:00AM
Abstract Number: 2297
Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System
Reproductive Issues In Rheumatic Disorders Poster
9:00AM-11:00AM
Abstract Number: 2128
Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality
Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies
9:00AM-11:00AM
Abstract Number: 2038
Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 2526
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
SLE – Clinical Poster III: Treatment
9:00AM-11:00AM
Abstract Number: 2555
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
SLE – Clinical Poster III: Treatment
9:00AM-11:00AM
Abstract Number: 2355
Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
RA – Treatments Poster III: Safety and Outcomes
9:00AM-11:00AM
Abstract Number: 2356
Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
RA – Treatments Poster III: Safety and Outcomes
9:00AM-11:00AM
Abstract Number: 1950
Apolipoprotein L1 Variant-Carrying Monocytes Exhibit Mitochondrial Respiration Defects
Genetics, Genomics & Proteomics Poster
9:00AM-11:00AM
Abstract Number: 2230
Applicability of FRAX in Clinical Practice: 10-year Results
Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster
  • «Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology